


02037593

Form 6-K



SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of May 2002

.....Teva Pharmaceutical Industries Limited.....
(Translation of registrant's name into English)

.....5 Basel Street, P.O. Box 3190.....
.....Petach Tikva 49131, Israel.....
(Address of principal executive offices)

PROCESSED

JUN 07 2002

THOMSON
FINANCIAL



Teva Pharmaceutical Industries Ltd.

Web Site www.tevapharm.com

Contact: Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical Industries Ltd.
(011) 972-2-589-2840

Bill Fletcher
President and CEO
Teva North America
(215) 591-8800

FOR IMMEDIATE RELEASE

Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical Industries Ltd.
(011) 972-3-926-7554

**TEVA ANNOUNCES FEDERAL JUDGE INVALIDATES
REMAINING AUGMENTIN PATENTS**

Jerusalem, Israel, May 23, 2002 – Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) announced that a federal judge has ruled today in its favor, invalidating the three remaining GlaxoSmithKline patents that were being challenged by generic manufacturers, otherwise due to expire by December 24, 2002, covering the antibiotic Augmentin®. The ruling follows two earlier decisions by the same court on March 13, 2002 and December 14, 2001 that invalidated four GlaxoSmithKline patents otherwise scheduled to expire in 2017 and 2018. The most recent ruling was issued by the federal judge from the bench immediately following the conclusion of the trial.

Teva currently has ANDAs pending before the FDA for amoxicillin and clavulanic acid (the generic equivalent of Augmentin®) and anticipates receiving FDA clearance in the near future. This product is an antibiotic and, accordingly, is not a product for which any generic manufacturer is entitled to any 180-day period of exclusivity.

Bill Fletcher, President and CEO of Teva North America commented, "We are very pleased with the court's decision, which we once again believe validates our decision to challenge the patents. Favorable rulings such as the one today only enhance our Company's ability to offer consumers cost-effective medication. While awaiting our ANDA approval, we will be taking the necessary steps to prepare ourselves for the launch of this very important product."

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and branded human pharmaceuticals and active pharmaceutical ingredients.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the beliefs and expectations of management. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such regulatory environment and changes in the health policies and structure of various countries, acceptance and demand for new pharmaceutical products and new therapies, the impact of competitive products and pricing, the availability and pricing of ingredients used in the manufacture of pharmaceutical products, uncertainties regarding market acceptance of innovative products newly launched, currently being sold or in development, the impact of restructuring of clients, reliance on a strategy of acquiring companies and on strategic alliances, exposure to product liability claims, dependence on patent and other protections for our innovative products, fluctuations in currency, exchange and interest rates, operating results, and other factors that are discussed in the Company's Annual Report on Form 20-F and the Company's other filings with the U. S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.

Teva Pharmaceutical
Industries Limited

.....
(Registrant)

By:


Dan Suesskind
Chief Financial Officer

Date: ~~May 24~~ 2002